Stock Market Review 28AUG23 #shorts

An FDA ad­vi­so­ry com­mit­tee rec­om­mend­ed against full ap­proval for Al­fasig­ma and In­ter­cept Phar­ma­ceu­ti­cals’ rare liv­er dis­ease drug Ocali­va by a 13-1 vote, con­clud­ing that con­fir­ma­to­ry

The FDA lift­ed a clin­i­cal hold on two tri­als test­ing Bio­mea Fu­sion’s di­a­betes treat­ment. The news, an­nounced Thurs­day, sent the com­pa­ny … Sign up to